listed (mainly with bDMARDs and tsDMARDs), followed by influenza. Common non-viral causes of infection were candida and tinea species. Variable or absent reporting was noted for opportunistic infections (e.g. tuberculosis and fungi) and certain high-prevalence viruses e.g. Epstein-Barr.

Conclusion: The SmPC literature reports differences in infection risk, by site and pathogen, between immune-modulatory drugs. The findings can be used to visualise differences and aid treatment decisions. However, some of the patterns we have shown lack face-validity to clinicians familiar with real-world safety data. The data fail to capture risk of rare infections, are likely skewed by trial selection criteria, varying number of trials per drug and quirks of individual study-reporting methodologies. The findings highlight the need for robust post-marketing pharmacovigilance studies.

REFERENCES:

- [1] A Guideline on Summary of Product Characteristics Module 1.3. 2008.

Drug & target		ENT	GI	LRTI	SKIN/SOFT TISSUE	URTI	UTI
Conventional synthetic drugs	Cladribine						
	Mycophenolate mofetil						
	Teriflunomide						
Targeted synthetic drugs	Janus kinase						
	Baricitinib						
	Fingolimod						
	Sphingosine 1-phosphate receptor						
	Fingolimod						
Biologic drugs	TNFα						
	Adalimumab						
	Etanercept						
	Golimumab						
	Infliximab						
	IL-6						
	Sarilumab						
	Tocilizumab						
	IL-17						
	Ixekizumab						
	Secukinumab						
	IL-12/23						
	Ustekinumab						
	IL-23						
	Guselkumab						
Cell-targeted	Complement C5						
	Eculizumab						
	Ravulizumab						
	Other cytokine/enzyme target						
	Anakinra						
	Canakinumab						
	Mitoxantrone						
	Abatacept						
	Alemtuzumab						
	Belimumab						

Figure 1: Summary of common sites of infection for immune-modulatory drugs.

Key: Very common (red circle); Common (orange circle); Uncommon (yellow circle); Rare (green circle); Blank: no information available

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2207

AB0650

SCREENING TESTS FOR LATENT TUBERCULOSIS OF CANDIDATES TO BIOLOGIC THERAPY: DATA FROM THE TUNISIAN BINAR REGISTRY

R. Ben Aissa¹, S. Boussaid², S. Kochbati¹, M. El Euch², A. Laatar³, L. Abdelmoula⁴, W. Hamdi⁵, E. Bouagina⁶, I. Gharsallah⁷, M. Younes⁸, N. Bergaoui⁹, S. Baklouti¹⁰. ¹Habib Thameur Hospital, Department of Internal Medicine, Tunis, Tunisia; ²Rabta Hospital, Department of Rheumatology, Tunis, Tunisia; ³Mongi Slim Hospital, Department of Rheumatology, Marsa, Tunisia; ⁴Charles Nicolle Hospital, Department of Rheumatology, Tunis, Tunisia; ⁵Med Taieb Kassab Institute, Department of Rheumatology, Mannouba, Tunisia; ⁶Farhat Hachad Hospital, Department of Rheumatology, Sousse, Tunisia; ⁷Military Hospital, Department of Internal Medicine, Tunis, Tunisia; ⁸Tahar Sfar Hospital, Department of

Rheumatology, Mahdia, Tunisia; ⁹Fattouma Bourguiba Hospital, Department of Rheumatology, Monastir, Tunisia; ¹⁰Hedi Chaker Hospital, Department of Rheumatology, Sfax, Tunisia

Background: The screening and treatment of latent tuberculosis infection (LTBI) is required before starting biologic therapy. Tuberculin skin test (TST) and interferon γ gamma release assay (IGRA) are the two commonly used tests.

Objectives: The aim of our study was to analyze data from the Biological National Registry BINAR between 2016 and 2020 in order to compare the diagnostic value of TST and IGRA tests.

Methods: We collected data of patients diagnosed with LTBI (having had a TST and/or IGRA before receiving any biotherapy) from the BINAR registry (a National Tunisian registry of patients with inflammatory rheumatic diseases under biologic therapy since less than two years from the inclusion date).

Results: From a total of 298 patients included in our study, 199 patients (66.8%) were screened by TST and 159 patients were screened (53.4%) by IGRA.

Thirty-four patients (11.4%) had a positive TST and 27 patients (9.1%) had a positive IGRA test.

Three patients having negative TST and two having negative IGRA developed tuberculosis.

There was no significant difference in our study between these two tests for LTBI diagnosis. The reactivation of tuberculosis can occur even when LTBI screening is negative using TST and IGRA tests.

Conclusion: Our results show that the predictive diagnostic value for these two tests is the same. It would be more interesting to practice one of those tests prior to biotherapy.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.2938

COVID-19

AB0651

CASE-REPORT: ORGANIZING PNEUMONIA IN A PREGNANT WOMAN WITH RHEUMATOID ARTHRITIS DURING COVID-19 PANDEMIC

A. Cornillie¹, C. Grivegne². ¹Erasme-ULB, Pneumology, Bruxelles, Belgium; ²Erasme-ULB, Pneumology, Bruxelles, Belgium

Conclusion: Case-report: Organizing pneumonia in a pregnant woman with rheumatoid arthritis during Covid-19 pandemic

CORNILLIE Alexia, GRIVEGNE Camille, CHU Charleroi Marie-Curie

Introduction

Rheumatoid arthritis (RA) is a systemic inflammatory disease characterized by destructive polyarthritis and extra-articular organ involvement. Lungs are one of the most commonly affected organ in RA, and the lung involvement in RA results in a various clinical features including interstitial lung disease (ILD) and organizing pneumonia (OP).

OP is a histologic term characterized by the presence of buds of granulation tissue in bronchioles and alveoli. OP can be either idiopathic (cryptogenic organizing pneumonia) or secondary to underlying disease such as infection, drugs or connective tissue disease including RA.

Lung biopsy is usually recommended for the diagnosis, but the following criteria fulfilled by patients can lead to the diagnosis: (1) specific radiological manifestations (nonsegmental randomized consolidation with/without ground glass opacities in chest CT), (2) no causative infectious agent, (3) no response to antibiotics and (4) good response to corticosteroid therapy.

We describe here the case of organized pneumonia discovered in a pregnant woman with known rheumatoid arthritis during COVID-19 pandemic.

Case description

A 39-year old moroccan woman, gravida 4, para 1, was admitted during COVID-19 pandemic at 30 weeks' gestation to maternity hospital with a 1-week history of cough, dyspnea and fever. Her medical history included rheumatoid arthritis and gestational diabetes. She was treated with 5mg of prednisolone daily for her RA. Blood sample showed white blood cell count and C reactive protein at a level of 6860/mm3 and 42mg/L respectively. Chest CT performed at her admission revealed diffuse irregular nodular condensations associated with ground glass infiltrates and a right lower lobe parenchymal condensation with airbronchogram in favor of superinfection. Given circumstances, she was tested twice for SARS-Cov-2 48 hours apart by PCR on nasopharyngeal sample and results came back negative. She was treated empirically with ceftriaxone and azithromycin during the first week and described an improvement in her clinical condition but symptoms reappeared 4 days after stopping treatment. During the 2 following months, until the delivery, the patient remained subpyretic with a nonproductive cough and moderate dyspnea. 5 days after the delivery, due

to persistent dyspnea and fever, a new chest CT was performed and revealed similar image findings but some of the irregular nodular condensations showed a reversed halo sign and had a migrating character. Considering this typical image findings, the absence of causative infectious agents (excluded by bronchoalveolar lavage performed after delivery) and the absence of response to antibiotics, we concluded with a diagnosis of OP secondary to RA without performing lung biopsy samples. A treatment with 48mg of methylprednisolone (and 100mg of azathioprine a few weeks later) was initiated. One month later, she showed a spectacular improvement in her clinical condition. A new chest CT highlighted disappearance of the majority of the ground glass areas and of all the condensations previously described. Methylprednisolone was then progressively tapered.

Conclusion

OP is a common pulmonary complication that can develop in RA. However, despite our research, we have not found any other clinical case describing this disorder during pregnancy with RA. Since OP is a non-specific inflammatory response to an aggression of the organism, could we consider that the pregnancy is a state of aggression capable of causing such a response?

In addition, this clinical case illustrates the diagnostic challenge of this pathology during the Covid-19 pandemic.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.49

AB0652

FERRITIN IS ASSOCIATED WITH THE SEVERITY OF LUNG INVOLVEMENT BUT NOT WITH WORSE PROGNOSIS IN PATIENTS WITH COVID-19: DATA FROM TWO ITALIAN COVID-19 UNITS

F. Carubbi¹, A. Alunno², L. Salvati³, C. Ferri¹, D. Grassi¹. ¹Internal Medicine and Nephrology Unit, University of L'Aquila, Department of Life, Health and Environmental Sciences, L'Aquila, Italy; ²Rheumatology Unit, University of Perugia, Department of Medicine, Perugia, Italy; ³Infectious Diseases Unit, Ospedale SS Filippo e Nicola ASL 1 Avezzano-Sulmona-L'Aquila, Department of Medicine, Avezzano, Italy

Background: The coronavirus 2019 disease (COVID-19) is characterised by a heterogeneous clinical presentation and a wide range of imaging findings, depending on disease severity and time course. The pathophysiology is complex, involving immune and hematologic systems, epithelial cells and vascular system and to date reliable biomarkers aimed at stratifying patients and predicting worse outcomes have not been identified

Objectives: The aim of this study was to describe clinical, serological and CT imaging features of a cohort of patients with COVID-19 pneumonia and identify possible relationships between the variables and disease outcomes (admission to intensive care unit (ICU) and/or death).

Methods: We evaluated hospitalized patients with proven SARS-CoV-2 infection, clinical signs of COVID-19 and computed tomography (CT) scan-proven pulmonary involvement. Clinical and serological records of patients admitted to two COVID-19 Units in Italy with proven SARS-CoV-2 pulmonary involvement investigated with CT scan, assessed at the time of admission to the hospital, were retrospectively collected.

Results: Sixty-one patients (22 females and 39 males) of median age 65 years were enrolled. Fifty-six patients were discharged while death occurred in 5 patients. None of the lung abnormalities detected by CT was different between discharged and deceased patients. No differences were observed in the features and extent of pulmonary involvement according to age and gender. Logistic regression analysis with age and gender as covariates demonstrated that ferritin levels over the 25th percentile were associated with the involvement of all 5 pulmonary lobes (OR=14.5, 95% CI=2.3-90.9, p=0.004), the presence of septal thickening (OR=8.2, 95% CI=1.6-40.9, p=0.011) and the presence of mediastinal lymph node enlargement (OR=12.0, 95% CI=1.1-127.5, p=0.039) independently of age and gender.

Conclusion: We demonstrated that ferritin levels over the 25th percentile are associated with a more severe pulmonary involvement, independently of age and gender, but not with disease outcomes (admission to ICU/death). The identification of reliable biomarkers in patients with COVID-19 may help guiding clinical decision, tailoring therapeutic approaches and ultimately improving the care and prognosis of patients with this disease.

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.61

AB0653

COURSE OF COVID-19 INFECTION IN A SERIES OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS

C. Cetin¹, N. Aliyeva¹, Y. Yalcinkaya¹, A. Gul¹, M. Inanc¹, B. Artim-Esen¹.

¹Istanbul Faculty of Medicine, Rheumatology, Istanbul, Turkey

Background: Infection is a remarkable cause of morbidity and mortality in patients with SLE.

Objectives: We aimed to determine the clinical course of COVID-19 infection in our patients with SLE and the factors affecting this course

Methods: SLE patients (2012 SLICC criteria) diagnosed with COVID-19 infection by a positive PCR test and/or typical findings of lung involvement in CT (computed tomography) imaging were included. Data regarding cumulative clinical and laboratory characteristics, histopathology results, autoantibody profiles, immunosuppressives and damage (SLICC damage index/SDI)) were retrieved from the existing database and revised. SLE Disease Activity Index (SLEDAI-2K) was determined at the time of infection.

Results: Sixteen SLE patients with COVID-19 infection were identified. Most (87.5%) of these patients were female. Seventy % (n=11) had lupus nephritis. Twenty-five % had thrombotic antiphospholipid syndrome.

PCR was positive in 70% (n=11) of the patients. Pulmonary parenchymal findings compatible with COVID-19 were observed in 56% (n=9) of those patients. Regarding complaints upon admission, 50% (n=8) had fever, 44% (n=7) cough, 44% (n=7) dyspnea, 19% (n=3) myalgia, 12.5% (n=2) headache, 12.5% (n=2) nausea/vomiting, 6% (n=1) diarrhea, and 6 % (n=1) had anosmia. Eight patients were hospitalized. Six of these patients needed oxygen therapy via nasal cannula. None needed a follow-up in the intensive care unit. The mean hospitalization duration was 14 ± 5 (8-25) days.

Regarding disease activity at the time of infection, 9 had inactive disease with a SLEDAI-2K score of 0 whilst in 5 patients SLEDAI-2K score was ≥4. The mean SLEDAI-2K score at the time of infection was 1.7 ± 2.3 (0-6). System/organwise, 1 patient with chronic thrombocytopenia presented with a worsening platelet count accompanied by serologic activity. This patient was a non-adherent to treatment who had stopped taking mycophenolic acid months before COVID19. Three patients 2 of whom had proliferative nephritis experienced nephritic flares. 1 patient who had a history of cutaneous lupus and was in remission presented with oral ulcer, leukopenia and hypocomplementemia during infection. Of 16 patients, 7 had system damage at the time of infection. The mean SDI score of the patients was 1.4±1.8. Comparison of patients with and without damage revealed no significant differences in disease activity, symptoms associated with COVID, in the need for hospitalization, hospitalization duration, and the requirement for oxygen therapy. However, CT findings compatible with COVID19, were more common in patients with damage (87% vs.33%, p=0.04) and their mean CRP levels were higher at diagnosis (65 ± 47 vs.22 ± 48 mg/l; p=0.032).

All patients received similar treatment for COVID-19 except active patients who required high dose steroids (2 with active renal, 1 with thrombocytopenia and 1 with oral ulcer, leukopenia and hypocomplementemia). The patient with thrombocytopenia also received intravenous immunoglobulin and 1 with cutaneous active disease received tocilizumab as she developed macrophage activation syndrome. Six patients (37.5%) had received rituximab (RTX) in the last 6 months before COVID. No significant difference, in terms of hospitalization and need for oxygen therapy due to COVID19 was found between patients who had received RTX vs who had not. No hypogammaglobulinemia was detected in patients who received RTX despite lower levels of IgG (998 ± 184 vs 1481 ± 51 mg/dl, p=0.02)

Conclusion: Although half of the patients in our series of COVID19 infected SLE patients required hospitalization, there were no mortalities. More patients with damage (none pulmonary) displayed CT findings compatible with COVID19 and further follow up will reveal whether they will suffer from fibrotic lung disease. Patients can experience disease flares during COVID. But it is also important to consider that some manifestations such as thrombocytopenia may also be a sign of severe infection. Immunosuppressive agents may not have a negative impact on the course of infection.

*the first two authors contributed equally

Disclosure of Interests: None declared.

DOI: 10.1136/annrheumdis-2021-eular.368

AB0654

TOCILIZUMAB IS PROTECTIVE AGAINST SARS-COV2 INFECTION OR NOT?

E. Fayed¹, E. Abdelkarim¹. ¹Alexandria University Students' Hospital, Rheumatology and Immunology Department, Alexandria, Egypt

Background: SARS-COV2 (Covid19) pandemic has a scaring burden on hospitals and health care providers all over the world. Unfortunately, after one year of pandemic, millions of persons are infected either mild symptoms or critical ones and unexplained deaths. Till now, No effective treatment or vaccination. Researches showed that Covid 19 associated with elevated interleukin-6. Subsequently, Studies reported that tocilizumab (IL-6 antagonist) may be effective in critical patients even though other were shown that it is not associated with reduction in the mortality.^(1,2) Therefore the question is that patients with rheumatic diseases who are already receiving tocilizumab having a primary